Post-Grafting Healthcare After Kidney Transplant STUDY ON IMMUNOSUPPRESSION DRUGS ON KIDNEY GRAFTED PATIENTS. DE
-
- Englisch ausgewählt
Fr. 61.90
inkl. gesetzl. MwSt.,
Beschreibung
Produktdetails
Einband
Taschenbuch
Erscheinungsdatum
29.08.2025
Verlag
LAP LAMBERT Academic PublishingSeitenzahl
72
Maße (L/B/H)
22/15/0.5 cm
Gewicht
125 g
Sprache
Englisch
ISBN
978-620-8-47290-0
POST-GRAFTING HEALTHCARE AFTER KIDNEY TRANSPLANT It is now well established that early kidney transplantation is associated with optimal outcomes in terms of patient and graft survival. In chronic kidney disease (CKD) - Stage V patients, kidney transplantation is considered as the treatment of choice because both survival and quality of life are often better than in people who are treated with dialysis. After kidney transplantation, patients receive a combination of immunosuppressive medications to prevent rejection of the transplanted kidney. Newer immunosuppressive drug regimens have resulted in improving the outcomes in kidney transplantation in the last two decades. These regimens usually contain a (CNI) calcineurin-inhibitor (tacrolimus or cyclosporine), steroids along with antiproliferative agent mycophenolate mofetil (MMF).The introduction of azathioprine as an effective oral immunosuppressant in the late 1950s resulted in achieving the first long-term survivors of transplants between genetically non-identical individuals (allografts). This drug acts by inhibiting purine synthesis.
Noch keine Bewertungen vorhanden
Verfassen Sie die erste Bewertung zu diesem Artikel
Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.